| Feasibility of a New Technology for Isolating Circulating Tumour Cells (NCT03979339) | Centre Oscar Lambret | 2020-03-11 |
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT02966587) | University of Washington | 2018-05-15 |
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer (NCT02881242) | Jonsson Comprehensive Cancer Center | 2018-01-30 |
| Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT02844582) | University of California, Davis | 2017-12-20 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer (NCT03122743) | Wake Forest University Health Sciences | 2017-02-22 |
| Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer (NCT02516670) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-06-20 |
| Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients (NCT02853097) | University of Southern California | 2016-06-14 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (NCT02567396) | National Cancer Institute (NCI) | 2016-06-01 |
| Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO (NCT04516707) | Institut du Cancer de Montpellier - Val d'Aurelle | 2016-01-01 |
| Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer (NCT02169063) | University of Washington | 2015-12-01 |
| Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (NCT02491411) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-09-01 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer (NCT02499835) | University of Wisconsin, Madison | 2015-07-01 |
| Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT02159950) | Roswell Park Cancer Institute | 2015-01-01 |
| Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer (NCT02370355) | University of Southern California | 2014-12-23 |
| Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide (NCT02312557) | OHSU Knight Cancer Institute | 2014-11-18 |
| Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer (NCT02215161) | University of California, San Francisco | 2014-09-02 |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer (NCT02184533) | Stanford University | 2014-07-01 |
| Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer (NCT01949337) | Alliance for Clinical Trials in Oncology | 2014-01-22 |
| Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer (NCT02012296) | University of Chicago | 2013-12-13 |
| Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01866423) | University of Southern California | 2013-10-25 |
| Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (NCT01848067) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-08-14 |
| Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T (NCT01833208) | Roswell Park Cancer Institute | 2013-07-03 |
| Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01913015) | OHSU Knight Cancer Institute | 2013-07-01 |
| Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (NCT01807065) | City of Hope Medical Center | 2013-06-07 |
| Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (NCT01953640) | Mayo Clinic | 2013-05-30 |
| Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (NCT01812668) | Barbara Ann Karmanos Cancer Institute | 2013-03-01 |
| Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer (NCT01802346) | University of Southern California | 2013-01-29 |
| Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01503229) | University of Washington | 2012-12-01 |
| Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01685125) | University of Southern California | 2012-09-01 |
| Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel (NCT01469338) | University of Southern California | 2012-07-01 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01498978) | OHSU Knight Cancer Institute | 2012-02-06 |
| Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer (NCT01533246) | National Cancer Institute (NCI) | 2012-02-01 |
| Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer (NCT01174199) | Roswell Park Cancer Institute | 2012-02-01 |
| Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01468532) | Barbara Ann Karmanos Cancer Institute | 2011-10-01 |
| Saracatinib in Treating Patients With Prostate Cancer (NCT01267266) | National Cancer Institute (NCI) | 2010-12-01 |
| Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01240629) | University of Southern California | 2010-11-02 |
| Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01145508) | National Cancer Institute (NCI) | 2010-08-01 |
| Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel (NCT01253642) | OHSU Knight Cancer Institute | 2010-07-12 |
| Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer (NCT01093183) | University of Nebraska | 2010-03-04 |
| Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer (NCT01050842) | Mayo Clinic | 2010-02-01 |
| Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases (NCT00936975) | National Cancer Institute (NCI) | 2009-09-01 |
| Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00486642) | National Cancer Institute (NCI) | 2007-09-01 |
| AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00513071) | National Cancer Institute (NCI) | 2007-08-01 |
| Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer (NCT00570700) | University of California, Irvine | 2007-07-01 |
| Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer (NCT01338792) | University of Southern California | 2006-06-01 |
| Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00110214) | National Cancer Institute (NCI) | 2005-04-01 |
| Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer (NCT00541281) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2003-12-01 |
| BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy (NCT00040755) | National Cancer Institute (NCI) | 2002-05-01 |
| Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer (NCT00016107) | National Cancer Institute (NCI) | 2001-06-01 |